CLDN18.2-Specific CAR T-Cell Therapy Prolongs PFS in Patients with Previously Treated Advanced Gastric or Gastro-oesophageal Junction Cancer By Ogkologos - August 14, 2025 781 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CT041-ST-01 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR Rucaparib Extends PFS in the Maintenance Treatment of Recurrent EOC Without... September 1, 2020 ESMO Launches Living Guidelines to Enhance the Usability of its Clinical... May 10, 2023 A Blood-Based, Multigenomic Signature is an Effective Diagnostic and Has Clinical... August 16, 2021 6 of the biggest good news cancer stories of 2021 December 15, 2021 Load more HOT NEWS Mom Gives Birth and Receives a Breast Cancer Diagnosis on the... EMA Recommends Granting a Conditional Marketing Authorisation for Belantamab Mafodotin Opinion: “We’ve been pushing for change for 20 years. We’re not... FDA Approves Engineered Cell Therapy for Advanced Synovial Sarcoma
